Civantos is on staff at several area hospitals and sees patients at Illinois Retina’s Hinsdale, Joliet and Harvey office locations. He has been listed in Best Doctors in America and the Guide to America’s Top Ophthalmologists. Civantos holds memberships in several professional societies and organizations and serves on the Board of Directors for the Deicke Center for Visual Rehabilitation in Wheaton. He has published articles for several academic specialty journals and has presented on such topics as the management of dislocated intraocular lenses, ocular infections, diabetic vitrectomy, macular disease, photodynamic therapy in young patients and others. Civantos speaks extensively at ophthalmology meetings throughout the United States. Civantos has served as principal investigator for a number of major clinical trials over the years, involving the treatment of macular degeneration, diabetic retinopathy and retinal detachment.ĭr.
Civantos is certified by the American Board of Ophthalmology.Ī committed researcher, Dr. Civantos completed an ophthalmology residency at the Bascom Eye Institute in Miami, Florida followed by a retina-vitreous fellowship at Rush University Medical Center in Chicago. He received his undergraduate degree in biology from Harvard College in Cambridge, Massachusetts and medical training at the prestigious Columbia University College of Physicians and Surgeons in New York. Civantos inherited his passion for the practice of medicine from his father, who is also a physician.
He has been associated with Illinois Retina Associates since 1994.Ī native of Miami, Dr. Civantos is an Assistant Professor of Ophthalmology at Rush University Medical Center in Chicago. In addition to his busy medical practice, Dr. Civantos, MD, is a nationally recognized expert who specializes in the medical and surgical treatment of diseases of the retina and vitreous, including macular degeneration, retinal detachment, diabetic retinopathy, trauma to the eye and retinopathy of prematurity. Leading-Edge Intra-Arterial Chemotherapy for Children with Retinoblastoma. This treatment allows us to treat cancer without removing the eye preserving vision, independence, and quality of life.
FLORIDA RETINA INSTITUTE ONCOLOGY HOW TO
“I hope that we, as a whole learn how to recruit more effectively underrepresented populations so that going forward, we don't have to specifically create a study addressing one specific population but we can then use the things that we've learned from this trial to help with our going forward in future trials. “I hope that we learn more than just the results of how (faricimab) works for diabetic macular edema in underrepresented populations,” Cunningham said. The efficacy and safety of faricimab will be assessed in patients from African American, Hispanic, Latin American, and Indigenous communities throughout the Elevatum trial, which Matthew Cunningham, MD, of the Florida Retina Institute, believes to be the first industry-sponsored assessment regarding representation in DME trials.įor this episode of DocTalk, Cunningham sits down with managing editor Kevin Kunzmann to speak to the issue of representation in DME and other ophthalmology trials, and how DME disproportionately affects underrepresented populations.įurthermore, Cunningham details the burdens that patients from underrepresented communities face with trial inclusion standards. The newly approved ophthalmic drug faricimab (Vabysmo) has already made waves by being the first of its drug class to be approved for both diabetic macular edema (DME) and neovascular age-related degeneration (nAMD).Ī new phase 4 clinical trial from Genentech seeks to expand on the efficacy of the drug in patients with DME from underrepresented populations.
0 kommentar(er)
